MedTrace Logo

First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration

NCT02076919 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2016-04-01

Study results available
· View outcomes & findings →

Summary

The purpose of this first-in-human study is to assess the local ocular and systemic safety and tolerability of LHA510 eye drops when administered at various concentrations and dosing frequencies.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

LHA510 Ophthalmic Suspension

Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2

DRUG

LHA510 Vehicle

Inactive ingredients used for masking purposes

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Robert Maietta, BSc · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-06-30
Completion
2014-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02076919 on ClinicalTrials.gov